Table 1. Treatment completion rates.

Group	Treatment	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6
Study 1
1	CON	100% (16/16)	100% (16/16)	100% (16/16)	100% (16/16)	100% (16/16)	100% (16/16)
2	CIS	100% (16/16)	100% (16/16)	100% (16/16)	100% (16/16)	87% (14/16)	87% (14/16)
3	CON + EX	100% (18/18)	100% (18/18)	100% (18/18)	100% (18/18)	100% (18/18)	100% (18/18)
4	CIS + EX	100% (18/18)	100% (18/18)	100% (18/18)	100% (18/18)	100% (18/18)	100% (18/18)
Study 2
1	CON	100% (9/9)	100% (9/9)	100% (9/9)	100% (9/9)	100% (9/9)	100% (9/9)
2	CIS	100% (10/10)	100% (10/10)	100% (10/10)	90% (9/10)	80% (8/10)	80% (8/10)
3	CIS + ONS	100% (10/10)	100% (10/10)	100% (10/10)	90% (9/10)	90% (9/10)	80% (9/10)
4	CIS + STER	100% (9/9)	100% (9/9)	100% (9/9)	88% (8/9)	88% (8/9)	78% (7/9)
5	CIS + STER + EX	100% (10/10)	100% (10/10)	100% (10/10)	100% (10/10)	100% (10/10)	90% (9/10)
6	CIS + EX	100% (10/10)	100% (10/10)	100% (10/10)	100% (10/10)	100% (10/10)	100% (10/10)
Study 3
1	CON	100% (9/9)	100% (9/9)	100% (9/9)	100% (9/9)	100% (9/9)	100% (9/9)
2	CIS	100% (9/9)	100% (9/9)	100% (9/9)	100% (9/9)	100% (9/9)	100% (9/9)
3	CIS + EX in recovery	100% (9/9)	100% (9/9)	100% (9/9)	100% (9/9)	100% (9/9)	100% (9/9)

Percentage and number of mice completing cisplatin treatment. CON: Saline treated mice, CIS: cisplatin treated mice, ONS: Onsedansetron, STER: steroids, dexamethasone, EX: access to running wheels, and CIS + EX in recovery: access to running wheels in the 6 weeks recovery phase.

In study 1 in each group, the mice were divided between termination at rest or after 1 hour of acute exercise (swimming). Both groups had the following measurements made: body weight, food intake, weight of organs at termination and blood sampling at termination. In addition, the rest group were DXA scanned, performed the hang tests and had a glucose tolerance test made.